WebMar 13, 2024 · Background: Post-transplant cyclophosphamide (PTCY) is increasingly used for allogeneic peripheral blood stem cell transplantation (allo-PBSCT) from an HLA-matched unrelated donor (MUD) as an... WebSep 13, 2014 · In the allo-PBSCT/BMT group, only three patients died due to transplant-related complications, and the causes of death were refractory aGVHD (61 days after transplantation), post-transplant lymphoproliferative disease (PTLD) (289 days after transplantation), and cGVHD combined with cerebral infarction (382 days after …
Allogeneic peripheral blood stem cell transplantation …
WebJul 15, 2013 · Allogenic peripheral blood stem cell transplantation (Allo-PBSCT) is being used to treat hematological malignancies with increasing frequency. Allo-PBSCT has many complications, such as infections, veno-occlusive disease of the liver, drug reactions, and graft-versus-host disease (GvHD). WebSep 14, 2024 · The 2-years cumulative disease-free survival (DFS) were (57.1±12.4)% and (53.5±10.6)% for auto-PBSCT and allo-PBSCT respectively (P=0.701). In patients with dead outcomes after PBSCT, 83.3%... mortgageapplicationservice ie
Author notes - American Society of Hematology
WebJun 1, 2024 · As for diagnosis, leukemia patients carried a greater risk of CMV viremia (OR = 5.2, 95% CI 1.52∼17.7, p = 0.008). Ninety-five percent (17/18) of patients of the viremia group received allo-peripheral blood stem cell transplantation (PBSCT), which increased the risk of CMV viremia (OR = 14.57, 95% CI 1.76∼120.5; p = 0.002). WebFifteen patients (75.0%) who had no HLA-matched donor underwent unrelated cord blood transplantation (UCBT), 4 patients (20.0%) underwent allogeneic HLA-matched peripheral blood stem cell transplantation (allo-PBSCT), and 1 … Webf• 造血干细胞移植 • 造血干细胞移植(HSCT)是指将供者的造血干细胞(HSC)移植到受者体内,以重建受者的造血和免疫. 功能,从而达到治愈某些疾病的一种方法。. • 1957年 Thomas 骨髓移植. • 治疗策略是采用超大剂量化疗和全身放疗,达到清除肿瘤细胞或 ... mortgage application service bank of ireland